We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Read MoreHide Full Article
Moderna (MRNA - Free Report) closed the most recent trading day at $66.98, moving -1.89% from the previous trading session. This change lagged the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 1.55%.
Prior to today's trading, shares of the biotechnology company had gained 36.79% outpaced the Medical sector's gain of 5.5% and the S&P 500's gain of 4.28%.
Market participants will be closely following the financial results of Moderna in its upcoming release. The company plans to announce its earnings on July 31, 2026. The company is predicted to post an EPS of -$1.97, indicating a 7.51% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $114.89 million, reflecting a 19.09% fall from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$8.34 per share and revenue of $2.08 billion, which would represent changes of -14.88% and +7.04%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.85% lower. Right now, Moderna possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 108, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Moderna (MRNA) Registers a Bigger Fall Than the Market: Important Facts to Note
Moderna (MRNA - Free Report) closed the most recent trading day at $66.98, moving -1.89% from the previous trading session. This change lagged the S&P 500's daily loss of 0.79%. On the other hand, the Dow registered a loss of 0.26%, and the technology-centric Nasdaq decreased by 1.55%.
Prior to today's trading, shares of the biotechnology company had gained 36.79% outpaced the Medical sector's gain of 5.5% and the S&P 500's gain of 4.28%.
Market participants will be closely following the financial results of Moderna in its upcoming release. The company plans to announce its earnings on July 31, 2026. The company is predicted to post an EPS of -$1.97, indicating a 7.51% growth compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $114.89 million, reflecting a 19.09% fall from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$8.34 per share and revenue of $2.08 billion, which would represent changes of -14.88% and +7.04%, respectively, from the prior year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Moderna. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.85% lower. Right now, Moderna possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 108, which puts it in the top 44% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.